 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
| «12...3456789101112131415» |
- Xpovio (selinexor) / Ono Pharma, Karyopharm, Antengene
[VIRTUAL] ESTIMATING THE COST-EFFECTIVENESS OF BELANTAMAB MAFODOTIN VERSUS APPROPRIATE TREATMENT COMPARATORS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE UNITED STATES () - Apr 11, 2021 - Abstract #AMCP2021AMCP_54;
P2, P2b
Belamaf is dominant (less costly and more effective) versus SEL+DEX. Belamaf incremental costs per QALY gained and its estimated cost per QALY versus basket SoC were consistent with the acceptable cost-effectiveness thresholds for US value-based price benchmarks (<$150k/ QALY; ICER 2020-23 Value Assessment Framework).
- | Darzalex IV (daratumumab) / J&J
Journal, IO biomarker: CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. (Pubmed Central) - Apr 7, 2021
Lastly, we evaluate the impact of exposure to all-trans retinoic acid (ATRA) on wild type NK and CD38KO NK cells function and highlight potential benefit and drawbacks of combining ATRA with DARA in patients with MM. Taken together, these findings provide proof of concept that adoptive immunotherapy using ex vivo expanded CD38KO NK cells has the potential to boost DARA activity in MM.
- || Review, Journal: Boosting Immunity against Multiple Myeloma. (Pubmed Central) - Apr 7, 2021
In this sense, approaches that target not only myeloma cells but also the surrounding microenvironment are promising strategies to achieve a sustained MRD negativity with prolonged survival. This review provides an overview of current and future strategies used for immunomodulation of MM focusing on the impact on bone marrow (BM) immunome.
- || Darzalex IV (daratumumab) / J&J
Review, Journal: Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma. (Pubmed Central) - Apr 7, 2021
Belantamab mafodotin is the first approved antibody drug conjugate directed against B cell maturation antigen and is currently used as a monotherapy for patients with advanced disease. This review focuses on clinical efficacy and safety of monoclonal antibodies as well as antibody drug conjugates in multiple myeloma.
- || Darzalex IV (daratumumab) / J&J
Review, Journal: Targeted Therapy With Immunoconjugates for Multiple Myeloma. (Pubmed Central) - Apr 2, 2021
This review will focus on the mechanisms of action, safety and efficacy of several promising immunoconjugates that are under investigation in preclinical and/or clinical MM studies. We will also include a discussion on combination therapy with immunoconjugates, resistance mechanisms, and future developments.
- Darzalex IV (daratumumab) / J&J
[VIRTUAL] SAFETY, TOLERABILITY AND RESPONSE RATES OF DARATUMUMAB IN PATIENTS WITH RELAPSED LIGHT CHAIN (AL) AMYLOIDOSIS: RESULTS OF A PHASE II STUDY () - Mar 27, 2021 - Abstract #ISOA2020ISOA_360;
P1/2
Daratumumab infusion is well tolerated in patients with AL amyloidosis when administered with appropriate supportive care. A rapid hematologic response after 1 dose of daratumumab is seen in patients with AL amyloidosis.
- Darzalex IV (daratumumab) / J&J
[VIRTUAL] ASSESSMENT OF MINIMAL RESIDUAL DISEASE USING MULTIPARAMETRIC FLOW CYTOMETRY IN TREATED PATIENTS WITH AL AMYLOIDOSIS () - Mar 27, 2021 - Abstract #ISOA2020ISOA_38;
For patients with AL amyloidosis in hemCR, MRD-negativity by MFC was associated with statistically higher probability of renal response, but not cardiac or any organ response, nor depth of organ improvement. Results may be confounded by higher baseline dFLC and MRD testing occurring at a later time point after hemCR achievement in the MRD-negative cohort (71 vs. 32 months, P=.27), thereby allowing more time for organ recovery.
- || Darzalex IV (daratumumab) / J&J
Review, Journal: CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond. (Pubmed Central) - Mar 26, 2021
These aspects, together with their interaction with Fc receptors (FcRs) and neonatal FcRs, are specifically addressed in this paper. Moreover, the initiallyavailable experiences with the anti-CD38 MoAb DARA in AL amyloidosis are reviewed.
- | Blenrep (belantamab mafodotin) / GSK
Journal: Bispecifics, trispecifics, and other novel immune treatments in myeloma. (Pubmed Central) - Mar 26, 2021
Belantamab mafodotin, a B-cell maturation antigen (BCMA)-targeted ADC, has shown response rates >30% in a phase 2 trial of highly refractory patients and is being investigated in a variety of settings and combinations...This is an area of active preclinical research at this time. Lastly, designed ankyrin repeat proteins, which are small antibody-mimetic proteins with high target-binding affinity, have the potential to block multiple pathways at once and provide stimulatory signals to the immune system.
- | lenalidomide / Generic mfg., Darzalex IV (daratumumab) / J&J
Journal: Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group. (Pubmed Central) - Mar 26, 2021
DARA was generally well tolerated; however, 2 patients interrupted their therapy due to adverse events. Present real-life experience confirms that DARA monotherapy is an effective strategy for heavily pre-treated and refractory patients with multiple myeloma, with a favorable safety profile.
- Blenrep (belantamab mafodotin) / GSK
[VIRTUAL] BELANTAMAB MAFODOTIN IN HEAVILY TREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A CASE-SERIES FROM A REAL-LIFE EXPERIENCE () - Mar 25, 2021 - Abstract #EMN2021EMN_157;
Based on the IMWG criteria, the patient achieved a PR after the first 4 cycles of therapy and the treatment is still ongoing. BM demonstrates single agent activity for RRMM heavily treated patients and represents a new efficacy modality of therapy
- ciltacabtagene autoleucel (LCAR-B38M) / J&J
[VIRTUAL] CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA: ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE () - Mar 25, 2021 - Abstract #EMN2021EMN_146;
P1b
Some patients with heavily pretreated MM showed rapid and clinically meaningful improvements in pain, fatigue, physical functioning, overall HRQoL, and future perspectives, consistent with their clinical outcomes. With additional follow-up, these early improvements in symptoms may translate into greater overall HRQoL improvements in the long term.
- Melflufen (melphalan flufenamide) / Oncopeptides, Darzalex IV (daratumumab) / J&J
[VIRTUAL] ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE (DEX) AND DARATUMUMAB (DARA) OR BORTEZOMIB (BTZ) IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMID AND/OR A PROTEASOME INHIBITOR (PI) — UPDATED EFFICACY AND SAFETY () - Mar 25, 2021 - Abstract #EMN2021EMN_143;
P1/2
Melflufen + dex as a triplet regimen with dara or BTZ has encouraging activity and was well tolerated in pts with RRMM. Analysis of the dara arm in more pts with longer follow-up suggests consistent responses with continued therapy.
- Blenrep (belantamab mafodotin) / GSK
[VIRTUAL] PATIENT-REPORTED EXPERIENCES DURING AND FOLLOWING TREATMENT WITH BELANTAMAB MAFODOTIN (BELAMAF) FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE DREAMM-2 STUDY () - Mar 25, 2021 - Abstract #EMN2021EMN_142;
P2
Many patients reported ocular symptoms but improved or resolved by EOT. Patients reported high levels of satisfaction while on treatment and a desire to remain on treatment.
- Melflufen (melphalan flufenamide) / Oncopeptides
[VIRTUAL] HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) EXPOSED TO PRIOR ALKYLATOR THERAPY—SUBGROUP ANALYSIS () - Mar 25, 2021 - Abstract #EMN2021EMN_140;
P2
Durable responses were observed in all subgroups analyzed, including pts refractory to alkylators in multiple prior LoTs. These results are intriguing, support the activity of melflufen in RRMM exposed to prior alkylators and should be verified in larger cohorts.
- Melflufen (melphalan flufenamide) / Oncopeptides
[VIRTUAL] HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE IN 55 PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE—SUBGROUP ANALYSIS () - Mar 25, 2021 - Abstract #EMN2021EMN_139;
P2
The safety profile of melflufen + dex was consistent with that of previous reports. To date, this clinical study provides the largest cohort of pts with EMD, demonstrating benefit of melflufen + dex in this population with high unmet medical need and supporting further evaluation of melflufen + dex in RRMM with EMD.
- Melflufen (melphalan flufenamide) / Oncopeptides
[VIRTUAL] How to overcome microenvironment induced drug resistance and novel agents in heavily pre-treated patients () - Mar 25, 2021 - Abstract #EMN2021EMN_88;
Melflufen is a novel alkylator based peptide-drug conjugate (PDC) with DNA damaging effect but has also been described to have anti-angiogenic properties...In summary, although agents exclusively targeting the microenvironment in MM have not been very successful to date in monotherapy, many of the novel anti-MM agents that are currently under evaluation play also a role on the MM microenvironment, which contributes to their efficacy. Finding the best combination of agents targeting the myeloma, stromal, immune and bone compartments is one of the challenges facing the treatment of heavily-pretreated patients.
- | Xpovio (selinexor) / Ono Pharma, Karyopharm, Antengene
Journal, IO biomarker: Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma. (Pubmed Central) - Mar 25, 2021
Selinexor represents a novel, oral agent with an innovative mechanism of action that offers a significant therapeutic advance in this group of heavily treated patients. Moreover, this novel mechanism may provide additional options for patients with less refractory disease.
- || Review, Journal, IO biomarker: CD38 and Regulation of the Immune Response Cells in Cancer. (Pubmed Central) - Mar 18, 2021
Targeting CD38 with anti-CD38 monoclonal antibodies in hematological malignancies has shown excellent results. Bearing that in mind, targeting CD38 in other nonhematological cancer types, especially carcinomas, which are of epithelial origin with specific anti-CD38 antibodies alone or in combination with immunomodulatory drugs, is an interesting option that deserves profound consideration.
- | Revlimid (lenalidomide) / BMS
Journal: Immunotherapy in multiple myeloma: when, where, and for who? (Pubmed Central) - Mar 16, 2021
Bearing that in mind, targeting CD38 in other nonhematological cancer types, especially carcinomas, which are of epithelial origin with specific anti-CD38 antibodies alone or in combination with immunomodulatory drugs, is an interesting option that deserves profound consideration. Immunotherapy is incorporated into first-line and relapse regimens, and is improving the survival of both newly diagnosed and relapsed/refractory multiple myeloma patients.
- Darzalex IV (daratumumab) / J&J, Sarclisa (isatuximab-irfc) / Sanofi
[VIRTUAL] Anti-CD38 interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping () - Mar 11, 2021 - Abstract #AACR2021AACR_3334;
P3
This reflects distinct mechanisms of CD38 binding. In the absence of human plasma, CD38 on RBCs can be directly recognized by Dara while Isa requires a cofactor, such as an anti-CD38 antibody or an NAD analog.
- Darzalex IV (daratumumab) / J&J
[VIRTUAL] Understanding the anti-tumor activities of daratumumab in natural killer/T cell lymphoma (NKTCL) () - Mar 11, 2021 - Abstract #AACR2021AACR_2886;
P2
In the absence of human plasma, CD38 on RBCs can be directly recognized by Dara while Isa requires a cofactor, such as an anti-CD38 antibody or an NAD analog. These results demonstrate that DARA can lead to clinical response in patients with NKTCL by modulating the immune environment.
- FT536 / Fate Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
[VIRTUAL] FT536: Preclinical development of a novel off-the-shelf CAR-MICA/B NK cell immunotherapy combined with radiation and antibody treatments as a first-of-kind pan-cancer targeting strategy () - Mar 11, 2021 - Abstract #AACR2021AACR_1414;
Ongoing work is focused on the development of in vivo models that combine FT536 with in situ tumor irradiation and mAbs in order to promote durable responses and the elimination of resistant and heterogenous cancer cells. These data demonstrate successful targeting of MICA/B positive tumors by FT536 can be augmented by mAb and radiation therapies as first-of-kind combinatorial strategies to broadly target escape-prone tumors.
- | Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
Biomarker, Clinical Trial,Phase II, Journal: Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. (Pubmed Central) - Mar 9, 2021
P2
Almost all patients had grade 3 or 4 toxic effects, most commonly hematologic toxic effects and cytokine release syndrome. (Funded by bluebird bio and Celgene, a Bristol-Myers Squibb company; KarMMa ClinicalTrials.gov number, NCT03361748.).
- || Revlimid (lenalidomide) / BMS, Darzalex IV (daratumumab) / J&J
Review, Journal: Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments. (Pubmed Central) - Mar 9, 2021
These studies provided results never seen before in this setting. The aim of this paper is to critically review the results obtained with regimens containing daratumumab both in relapsed-refractory and in newly diagnosed MM.
- || Review, Journal, IO biomarker: B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. (Pubmed Central) - Mar 5, 2021
Immunotherapeutic agents have been at the forefront of research designed to block BCMA activity. These agents encompass monoclonal antibodies, such as the drug conjugate belantamab mafodotin; bispecific T-cell engager strategies exemplified by AMG 420; and chimeric antigen receptor (CAR) T-cell therapeutics that include idecabtagene vicleucel (bb2121) and JNJ-68284528.
- | Melflufen (melphalan flufenamide) / Oncopeptides, Darzalex IV (daratumumab) / J&J
Journal: Melflufen for relapsed and refractory multiple myeloma. (Pubmed Central) - Mar 4, 2021
The safety profile of melflufen, which is characterized primarily by clinically manageable hematologic adverse events, is described. Melflufen has potential to fill a gap in the myeloma treatment landscape by providing a new mechanism of action with clinically meaningful efficacy and a favorable safety profile in patients refractory to multiple novel agents.
- | Darzalex IV (daratumumab) / J&J
Journal: Daratumumab interference in flow cytometric anti-granulocyte antibody testing can be overcome using non-human blocking antibodies. (Pubmed Central) - Feb 26, 2021
DTT treatment increased background binding of secondary antibodies causing a decrease in Flow-GIFT sensitivity. In comparison, blockage of the DARA binding epitope using mouse anti-CD38 antibody was effective in neutralizing DARA interference while maintaining Flow-GIFT sensitivity.
- || Darzalex IV (daratumumab) / J&J
Clinical, Journal, Monotherapy: Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia. (Pubmed Central) - Feb 26, 2021
P=N/A
In comparison, blockage of the DARA binding epitope using mouse anti-CD38 antibody was effective in neutralizing DARA interference while maintaining Flow-GIFT sensitivity. These EAP results are consistent with those from previous trials of daratumumab monotherapy and confirm its safety in patients from Europe and Russia with heavily pre-treated RRMM.
- || Darzalex Faspro (daratumumab/hyaluronidase) / J&J
Review, Journal: Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. (Pubmed Central) - Feb 23, 2021
Otherwise, the pharmacokinetics, safety profile, and efficacy are comparable. This review summarizes the pivotal trials that led to the approval of Dara-SC, highlights important clinical considerations for the use of Dara-SC, and provides practical guidelines for the administration of Dara-SC in the clinic.
- Darzalex IV (daratumumab) / J&J
[VIRTUAL] AN UNEXPECTED FINAL DIAGNOSIS IN A PATIENT WITH REFRACTORY ANGINA AND ELECTRICAL STORM (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_3588;
HT in cardiac AL amyloidosis is associated with a poor post-HT survival. New treatments, like monoclonal antibodies targeting CD38, could potentially improve the prognosis of these patients.
- ciltacabtagene autoleucel (LCAR-B38M) / J&J
[VIRTUAL] PATIENT EXPECTATIONS AND PERCEPTIONS OF TREATMENT IN CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2463;
P1b
Pretreatment expectations of cilta-cel were met/exceeded, and most patients reported their experience was better than with prior MM treatment. Clinical Trial Registry: NCT03548207https://clinicaltrials.gov/ct2/show/NCT03548207?term=NCT03548207&draw=2&rank=1
- ciltacabtagene autoleucel (LCAR-B38M) / J&J
[VIRTUAL] PATIENT EXPECTATIONS AND PERCEPTIONS OF TREATMENT IN CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2462;
P1b
Pretreatment expectations of cilta-cel were met/exceeded, and most patients reported their experience was better than with prior MM treatment. Clinical Trial Registry: NCT03548207https://clinicaltrials.gov/ct2/show/NCT03548207?term=NCT03548207&draw=2&rank=1
- ciltacabtagene autoleucel (LCAR-B38M) / J&J
[VIRTUAL] PATIENT EXPECTATIONS AND PERCEPTIONS OF TREATMENT IN CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2461;
P1b
Pretreatment expectations of cilta-cel were met/exceeded, and most patients reported their experience was better than with prior MM treatment. Clinical Trial Registry: NCT03548207https://clinicaltrials.gov/ct2/show/NCT03548207?term=NCT03548207&draw=2&rank=1
- ciltacabtagene autoleucel (LCAR-B38M) / J&J
[VIRTUAL] PATIENT EXPECTATIONS AND PERCEPTIONS OF TREATMENT IN CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2460;
P1b
Pretreatment expectations of cilta-cel were met/exceeded, and most patients reported their experience was better than with prior MM treatment. Clinical Trial Registry: NCT03548207https://clinicaltrials.gov/ct2/show/NCT03548207?term=NCT03548207&draw=2&rank=1
- ciltacabtagene autoleucel (LCAR-B38M) / J&J
[VIRTUAL] HEALTH-RELATED QUALITY OF LIFE IN THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2443;
P1b
With additional follow-up, these early improvements in symptoms may translate into greater overall HRQoL improvements in the long term. Clinical Trial Registry: NCT03548207https://clinicaltrials.gov/ct2/show/NCT03548207?term=NCT03548207&draw=2&rank=1
- ciltacabtagene autoleucel (LCAR-B38M) / J&J
[VIRTUAL] HEALTH-RELATED QUALITY OF LIFE IN THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2442;
P1b
With additional follow-up, these early improvements in symptoms may translate into greater overall HRQoL improvements in the long term. Clinical Trial Registry: NCT03548207https://clinicaltrials.gov/ct2/show/NCT03548207?term=NCT03548207&draw=2&rank=1
- ciltacabtagene autoleucel (LCAR-B38M) / J&J
[VIRTUAL] HEALTH-RELATED QUALITY OF LIFE IN THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2441;
P1b
With additional follow-up, these early improvements in symptoms may translate into greater overall HRQoL improvements in the long term. Clinical Trial Registry: NCT03548207https://clinicaltrials.gov/ct2/show/NCT03548207?term=NCT03548207&draw=2&rank=1
- ciltacabtagene autoleucel (LCAR-B38M) / J&J
[VIRTUAL] HEALTH-RELATED QUALITY OF LIFE IN THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (ePoster Area) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2440;
P1b
With additional follow-up, these early improvements in symptoms may translate into greater overall HRQoL improvements in the long term. Clinical Trial Registry: NCT03548207https://clinicaltrials.gov/ct2/show/NCT03548207?term=NCT03548207&draw=2&rank=1
- OPD5 / Oncopeptides
[VIRTUAL] COAST (OP-501): FIRST IN MAN PHASE I MULTICENTER STUDY EVALUATING OPD5 AS A MYELOABLATIVE CONDITIONING REGIMEN IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2208;
As OPD5 has similar preclinical pharmacokinetic and lipophilic properties as melflufen, it is of significant medical interest to investigate the benefit-risk profile of OPD5 as a conditioning regimen in patients where salvage ASCT is not currently considered standard of care. Findings from this first-in-man study will potentially demonstrate the value of OPD5 as a myeloablative therapy followed by stem cell support, justifying further clinical development.
- OPD5 / Oncopeptides
[VIRTUAL] COAST (OP-501): FIRST IN MAN PHASE I MULTICENTER STUDY EVALUATING OPD5 AS A MYELOABLATIVE CONDITIONING REGIMEN IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2207;
As OPD5 has similar preclinical pharmacokinetic and lipophilic properties as melflufen, it is of significant medical interest to investigate the benefit-risk profile of OPD5 as a conditioning regimen in patients where salvage ASCT is not currently considered standard of care. Findings from this first-in-man study will potentially demonstrate the value of OPD5 as a myeloablative therapy followed by stem cell support, justifying further clinical development.
- OPD5 / Oncopeptides
[VIRTUAL] COAST (OP-501): FIRST IN MAN PHASE I MULTICENTER STUDY EVALUATING OPD5 AS A MYELOABLATIVE CONDITIONING REGIMEN IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2206;
As OPD5 has similar preclinical pharmacokinetic and lipophilic properties as melflufen, it is of significant medical interest to investigate the benefit-risk profile of OPD5 as a conditioning regimen in patients where salvage ASCT is not currently considered standard of care. Findings from this first-in-man study will potentially demonstrate the value of OPD5 as a myeloablative therapy followed by stem cell support, justifying further clinical development.
- OPD5 / Oncopeptides
[VIRTUAL] COAST (OP-501): FIRST IN MAN PHASE I MULTICENTER STUDY EVALUATING OPD5 AS A MYELOABLATIVE CONDITIONING REGIMEN IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_2205;
As OPD5 has similar preclinical pharmacokinetic and lipophilic properties as melflufen, it is of significant medical interest to investigate the benefit-risk profile of OPD5 as a conditioning regimen in patients where salvage ASCT is not currently considered standard of care. Findings from this first-in-man study will potentially demonstrate the value of OPD5 as a myeloablative therapy followed by stem cell support, justifying further clinical development.
- | Revlimid (lenalidomide) / BMS, Darzalex IV (daratumumab) / J&J
Journal: Emerging drugs for the treatment of light chain amyloidosis. (Pubmed Central) - Feb 4, 2021
Other plasma cell-directed drugs that have prospective data on safety and efficacy in AL include proteasome inhibitors [bortezomib and ixazomib], immunomodulatory drugs [lenalidomide and pomalidomide], and alkylating agents [melphalan and bendamustine]...The most promising second line drugs are venetoclax [for t(11;14)] and pomalidomide, with several others in the pipeline, including antibody-drug conjugates. Minimal residual disease will emerge as a new endpoint for drug development and will potentially guide treatment duration.
- | Journal, IO biomarker: Identification and Targeting of Thomsen-Friedenreich and IL1RAP Antigens on Chronic Myeloid Leukemia Stem Cells Using Bi-Specific Antibodies. (Pubmed Central) - Feb 2, 2021
These results show that the bi-specific antibody is capable of targeting IL1RAP+ and CD176+ cell population among CML PBMCs, but not corresponding normal cells in CDC assay. We hereby offer a novel strategy for the depletion of CML stem cells from the bulk population in clinical hematopoietic stem cell transplantation.
- || Darzalex IV (daratumumab) / J&J
Clinical, Review, Journal: Epidemiology, Staging, and Management of Multiple Myeloma. (Pubmed Central) - Jan 28, 2021
Front-line management includes induction regimen, maintenance therapy and hematopoietic cell transplantation for eligible patients and bisphosphonates or bone-stimulating agents for the prevention of skeletal events. Treatment for relapsed disease includes newly approved monoclonal antibodies like the CD38-targeting daratumumab, proteasome inhibitors, immunomodulating agents, and investigational therapies such as B cell maturation antigen Chimeric antigen receptor T cells.
- ciltacabtagene autoleucel (LCAR-B38M) / J&J
[VIRTUAL] Health-Related Quality of Life in the CARTITUDE-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2407;
P1b
Some patients with heavily pretreated MM showed rapid and clinically meaningful improvements in pain, fatigue, physical functioning, overall HRQoL, and future perspectives, consistent with their clinical outcomes. With additional follow-up, these early improvements in symptoms may translate into greater overall HRQoL improvements in the long term.
- ciltacabtagene autoleucel (LCAR-B38M) / J&J
[VIRTUAL] Health-Related Quality of Life in the CARTITUDE-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2406;
P1b
Some patients with heavily pretreated MM showed rapid and clinically meaningful improvements in pain, fatigue, physical functioning, overall HRQoL, and future perspectives, consistent with their clinical outcomes. With additional follow-up, these early improvements in symptoms may translate into greater overall HRQoL improvements in the long term.
- ciltacabtagene autoleucel (LCAR-B38M) / J&J
[VIRTUAL] Health-Related Quality of Life in the CARTITUDE-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2405;
P1b
Some patients with heavily pretreated MM showed rapid and clinically meaningful improvements in pain, fatigue, physical functioning, overall HRQoL, and future perspectives, consistent with their clinical outcomes. With additional follow-up, these early improvements in symptoms may translate into greater overall HRQoL improvements in the long term.
- ciltacabtagene autoleucel (LCAR-B38M) / J&J
[VIRTUAL] Health-Related Quality of Life in the CARTITUDE-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2404;
P1b
Some patients with heavily pretreated MM showed rapid and clinically meaningful improvements in pain, fatigue, physical functioning, overall HRQoL, and future perspectives, consistent with their clinical outcomes. With additional follow-up, these early improvements in symptoms may translate into greater overall HRQoL improvements in the long term.